AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain. "We are excited to begin the journey of accelerating market penetration of Nevro's differentiated high-frequency technology and bringing a much-needed treatment option to ...

Globus Medical, Inc. (GMED) continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global musculoskeletal company focused on rapid innovation, addressing unmet clinical needs, and improving offerings to surgeons and patients. Additionally, its string of product launches is highly promising to drive growth in the coming quarters. Meanwhile, headwinds from adverse macroeconomic events and intense competition rema ...

Globus Medical (GMED) continues to gain from surging demand for its Musculoskeletal Solutions products. However, the challenging macroeconomic scenario continues to plague Globus Medical. The stock currently carries a Zacks Rank #3 (Hold).Factors Driving GMED's SharesGlobus Medical is gaining market share in the musculoskeletal solutions space, banking on the strong performance of its implantable devices, biologics, accessories and unique surgical instruments used in an expansive range of spinal, orthopedic ...

Core Viewpoint - Globus Medical, Inc. has launched two new products, the COHERE™ ALIF Spacer and Modulus™ ALIF Blades, aimed at enhancing surgical outcomes in anterior spine surgery through innovative technology and procedural efficiency [1][3][4]. Product Launches - The COHERE™ ALIF Spacer features proprietary porous surface technology that promotes bone in-growth while retaining the imaging and mechanical properties of solid PEEK interbody spacers [1][3]. - Modulus™ ALIF Blades provide surgeons with various fixation options using the same interbody spacer, improving procedural efficiency by reducing the number of surgical steps and instruments required [1][2]. Clinical Benefits - The integration of Porous PEEK technology is expected to enhance clinical outcomes for anterior cervical fusion and advance patient care in anterior lumbar spine surgery [1][4]. - The low-profile instrumentation and streamlined delivery of fixation with Modulus™ ALIF Blades may reduce complications by minimizing instrument passes near major vessels, thus allowing for a more minimally invasive approach [2][3]. Commitment to Innovation - Globus Medical emphasizes its dedication to advancing surgical outcomes and providing best-in-class solutions tailored to varying patient anatomies and surgeon preferences [4]. - The company aims to address unmet clinical needs through continuous innovation in product development [4][5].

Core Viewpoint - Globus Medical, Inc. has launched two new products, the COHERE™ ALIF Spacer and Modulus™ ALIF Blades, aimed at enhancing surgical efficiency and patient outcomes in anterior spine surgery [1][3][4] Product Launches - The COHERE™ ALIF Spacer features proprietary porous surface technology that promotes bone in-growth while retaining the imaging and mechanical properties of solid PEEK interbody spacers [1][3] - Modulus™ ALIF Blades provide surgeons with various fixation options using the same interbody spacer, improving procedural efficiency by reducing the number of surgical steps and instruments required [1][2] Clinical Benefits - The integration of Porous PEEK technology in the COHERE™ ALIF Spacer is expected to enhance clinical outcomes for anterior cervical fusion and lumbar spine surgery, with significant benefits in radiographic assessment of fusion [1][3] - The Modulus™ ALIF Blades are designed to minimize complications by reducing instrument passes near major vessels, thus allowing for a more minimally invasive surgical approach [2][3] Commitment to Innovation - Globus Medical emphasizes its dedication to advancing surgical outcomes and providing best-in-class solutions tailored to varying patient anatomies and surgeon preferences [4] - The company aims to address unmet clinical needs through continuous innovation in product development [4][5]

Core Viewpoint - Globus Medical, Inc. will participate in the 2025 Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS) in San Diego, showcasing its innovative musculoskeletal technology products and solutions [1][6]. Group 1: Event Participation - The event will take place from March 10-14, 2025, in San Diego, California [1]. - Globus Medical will host a booth (2517) to present its comprehensive product portfolio, including offerings in Spine, Trauma, Joint Reconstruction, Enabling Technology, Power Tools, and Regenerative Biomaterials [2]. Group 2: Featured Technologies - The company will highlight the ExcelsiusFlex™ surgical robotic navigation system for Total Knee Arthroplasty (TKA), designed for accuracy and procedural flexibility [3]. - Other featured products include the PRECICE™ Intramedullary Limb Lengthening Portfolio, DuraPro™ Oscillating System, and Harvest™ SmartPrep™ 3 autologous biologic centrifuge platform [4]. Group 3: Networking Opportunities - Globus Medical will host a reception for attendees to meet the team and learn more about their technology offerings on March 12, 2025, from 5:30 PM to 8:30 PM at the San Diego Wine & Culinary Center [5]. - An investor relations booth tour will also be conducted on March 12, 2025, from 1:00 PM to 1:45 PM, allowing analysts and investors to see the latest innovations [6]. Group 4: Company Overview - Globus Medical, based in Audubon, Pennsylvania, is a leading global musculoskeletal company focused on addressing unmet clinical needs and advancing care in various medical fields [7].

Core Insights - Globus Medical, Inc. is scheduled to present at the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego on March 10, 2025, at 4:30 pm PT [1] Company Overview - Globus Medical, Inc. is a leading global musculoskeletal technology company based in Audubon, Pennsylvania, focused on addressing unmet clinical needs and improving lives [3] - The company emphasizes innovation, education, clinical support, and advancements in various areas including spine, orthopedic trauma, joint reconstruction, regenerative biomaterials, and enabling technologies [3]

Group 1 - The stock of Globus Medical, Inc. (GMED) is experiencing significant attention due to high implied volatility in the options market, particularly for the Mar 21, 2025 $67.50 Call option [1] - Implied volatility indicates market expectations for future price movements, suggesting that investors anticipate a significant change in the stock's price, potentially due to an upcoming event [2] - Currently, Globus Medical holds a Zacks Rank 3 (Hold) in the Medical - Instruments industry, which is in the top 35% of the Zacks Industry Rank [3] Group 2 - Over the past 30 days, no analysts have increased their earnings estimates for the current quarter, while four analysts have revised their estimates downward, leading to a decrease in the Zacks Consensus Estimate from 79 cents per share to 76 cents [3] - The high implied volatility may indicate a developing trading opportunity, as options traders often seek to sell premium on options with high implied volatility to capture decay [4]

Mergers and Acquisitions - Siyata Mobile Inc. will be acquired by Core Gaming, with an exchange ratio based on a valuation of $160 million divided by the volume-weighted average closing price of Siyata's shares over the preceding 10 days [2] - Bridge Investment Group Holdings Inc. will be acquired by Apollo, with shareholders receiving 0.07081 shares of Apollo stock for each share of Bridge, valued at $11.50 per share [4] - Nevro Corp. will be acquired by Globus Medical for $5.85 per share, representing a total equity value of approximately $250 million [6] - 180 Degree Capital Corp. will merge with Mount Logan Capital Inc., with estimated post-merger ownership of approximately 40% for 180 Degree shareholders and 60% for Mount Logan shareholders [8] Investigations - Investigations are ongoing regarding whether the boards of Siyata, Bridge, Nevro, and 180 Degree breached their fiduciary duties by failing to conduct fair processes and whether shareholders are receiving fair value for their shares [2][4][6][8]

Core Viewpoint - Globus Medical, Inc. reported strong fourth-quarter 2024 results with adjusted earnings per share (EPS) of 84 cents, exceeding estimates and showing a 40% year-over-year increase [1][3] Financial Performance - The adjusted EPS for the full year was $3.04, a 31% increase from the previous year, surpassing estimates by 2% [3] - Total revenues for the full year reached $2.52 billion, reflecting a 60.6% increase year-over-year, exceeding estimates by 0.8% [4] - Worldwide sales increased by 6.6% year-over-year to $657.3 million, also surpassing estimates by 2% [3] Geographic Sales Breakdown - U.S. net sales increased by 6.3% year-over-year to $521.9 million, exceeding projections [5] - International revenues rose by 7.7% to $135.4 million, also surpassing estimates [5] Product Performance - Musculoskeletal Solutions generated revenues of $610.3 million, up 4.5% year-over-year, exceeding model projections [6] - Enabling Technologies saw revenues of $46.9 million, a significant 43.5% increase from the prior year, also surpassing estimates [6] Margin and Expense Analysis - Gross profit rose by 12.2% year-over-year to $393.9 million, with gross margin expanding to 60% [7] - SG&A expenses totaled $253.5 million, up 3.6% from the previous year, while R&D expenses decreased by 36.1% to $33.4 million [7] Cash Position - The company ended Q4 2024 with cash and cash equivalents of $890.1 million, up from $517.8 million at the end of 2023 [9] - Cumulative net cash from operating activities was $520.6 million, compared to $243.5 million the previous year [10] Future Guidance - For 2025, revenues are projected between $2.66 billion and $2.69 billion, with adjusted EPS expected in the range of $3.40 to $3.50 [11] - Following the acquisition of Nevro Corp. for $250 million, the company anticipates net sales of $2.80 billion to $2.90 billion and adjusted EPS of $3.10 to $3.40 for the full year [12] Overall Assessment - The performance indicates strong potential for the combined Globus-NuVasive organization, with record sales in Enabling Technologies and the introduction of five new innovative products [13]